Vaxcyte
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-12-01
- Employees
- 254
- Market Cap
- $8.7B
- Website
- http://www.vaxcyte.com
- Introduction
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 0.5 mL of the low dose VAX-31Biological: 0.5 mL of the mid dose VAX-31Biological: 0.5 mL of the high dose VAX-31Biological: 0.5 mL dose of PCV20
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT06720038
- Locations
- 🇺🇸
Orange County Research Institute, Ontario, California, United States
🇺🇸Center for Clinical Trials of San Gabriel, West Covina, California, United States
🇺🇸Children's Hospital of Colorado - Dept. of Infectious Disease, Aurora, Colorado, United States
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 20 valent pneumococcal conjugate vaccine
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 1015
- Registration Number
- NCT06151288
- Locations
- 🇺🇸
AMR Mobile, Mobile, Alabama, United States
🇺🇸AMR Phoenix, Phoenix, Arizona, United States
🇺🇸Research Centers of America, Hollywood, Florida, United States
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 0.5 ml dose of 2.2 mcg VAX-24Biological: 0.5 ml dose of 1.1 mcg VAX-24Biological: 0.5 ml dose of PCV20Biological: 0.5 ml dose of 2.2/4.4 mcg VAX-24
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 802
- Registration Number
- NCT05844423
- Locations
- 🇺🇸
UPMC Primary Care Center Oakland, Pittsburgh, Pennsylvania, United States
🇺🇸The Children's Clinic of Jonesboro, P.A., Jonesboro, Arkansas, United States
🇺🇸Madera Family Medical Group, Madera, California, United States
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
- Conditions
- Pneumococcal Vaccines
- Interventions
- Biological: 24-Valent Pneumococcal Conjugate Vaccine
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT05297578
- Locations
- 🇺🇸
Accel Research Sites-Birmingham Clinical Research Unit, Birmingham, Alabama, United States
🇺🇸Accel Research Sites - DeLand Clinical Research Unit, DeLand, Florida, United States
🇺🇸CenExel RCA, Hollywood, Florida, United States
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
- Conditions
- Pneumococcal Vaccines
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Vaxcyte, Inc.
- Target Recruit Count
- 835
- Registration Number
- NCT05266456
- Locations
- 🇺🇸
CenExel RCA, Hollywood, Florida, United States
🇺🇸Precision Clinical Research, Sunrise, Florida, United States
🇺🇸Meridian Clinical Research, Savannah, Georgia, United States
News
Vaxcyte's VAX-24 Shows Promising Results Despite Phase 2 Serotype Misses in Infant Study
Vaxcyte's Phase 2 study of VAX-24 pneumococcal vaccine missed four serotypes compared to Prevnar20 in infant data, causing a 50% drop in share price despite overall promising safety and immunogenicity profile.
Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Final Phase II Stage in Infant Trial
Vaxcyte has initiated the final stage of Phase II trials for VAX-31, its 31-valent pneumococcal conjugate vaccine, following successful safety review of Stage 1 data in infants.
Liraglutide Shows Promise in Pediatric Obesity, While Oncology Trials Face Setbacks
• Novo Nordisk's liraglutide demonstrated a significant reduction in BMI in a Phase III trial involving children aged 6-11, showing potential for pediatric obesity treatment. • Vaxcyte's VAX-31 pneumonia vaccine showed positive Phase I/II topline data, increasing its Phase Transition Success Rate (PTSR) in streptococcal pneumonia. • Pfizer terminated a Phase I trial of maplirpacept, leading to a decrease in its PTSR for peripheral T cell lymphoma and B cell Hodgkin lymphoma. • Les Laboratoires Servier's oncology drug trial was terminated due to business reasons, impacting the PTSR of S-64315 and S-65487 in multiple myeloma and leukemia.
Vaxcyte's VAX-31 Shows Promise in Broad-Spectrum Pneumococcal Disease Prevention
Vaxcyte's VAX-31 vaccine demonstrated a favorable safety profile and strong immune response against all 31 serotypes in adults aged 50 and older.
Vaxcyte's Pneumococcal Vaccine Candidate Outperforms Pfizer's Prevnar 20 in Early Trial
Vaxcyte's shares surged by 36% following the release of promising data on its pneumococcal vaccine candidate, VAX-24, which aims to rival Pfizer's Prevnar franchise.
Vaxcyte's VAX-31 Demonstrates Positive Phase 1/2 Results, Advancing to Phase 3 for Pneumococcal Disease
Vaxcyte's VAX-31, a 31-valent pneumococcal conjugate vaccine, showed robust immune responses against all 31 serotypes in a Phase 1/2 study.